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Abstract
Oncolytic peptides and peptidomimetics are being optimized for the treatment of cancer by selecting agents with
high cytotoxic potential to kill a maximum of tumor cells as well as the capacity to trigger anticancer immune
responses and hence to achieve long-term effects beyond therapeutic discontinuation. Here, we report on the
characterization of two novel oncolytic peptides, DTT-205 and DTT-304 that both selectively enrich in the lysosomal
compartment of cancer cells yet differ to some extent in their cytotoxic mode of action. While DTT-304 can trigger the
aggregation of RIP3 in ripoptosomes, coupled to the phosphorylation of MLKL by RIP3, DTT-205 fails to activate RIP3.
Accordingly, knockout of either RIP3 or MLKL caused partial resistance against cell killing by DTT-304 but not DTT-205.
In contrast, both agents shared common features in other aspects of pro-death signaling in the sense that their
cytotoxic effects were strongly inhibited by both serum and antioxidants, partially reduced by lysosomal inhibition
with bafilomycin A1 or double knockout of Bax and Bak, yet totally refractory to caspase inhibition. Both DTT-304 and
DTT-205 caused the exposure of calreticulin at the cell surface, as well as the release of HMGB1 from the cells. Mice
bearing established subcutaneous cancers could be cured by local injection of DTT-205 or DTT-304, and this effect
depended on T lymphocytes, as it led to the establishment of a long-term memory response against tumor-associated
antigens. Thus, mice that had been cured from cancer by the administration of DTT compounds were refractory
against rechallenge with the same cancer type several months after the disappearance of the primary lesion. In
summary, DTT-205 and DTT-304 both have the capacity to induce immunotherapeutic oncolysis.
Introduction
Peptides can be synthetically generated and potentially
provide pharmacological leads or final agents for multiple
purposes. In the field of cancer research, so-called onco-
lytic peptides have been conceived with the objective of
selectively killing tumor cells. This may be achieved by
fusing targeting sequences (that interact with proteins
specifically expressed on the surface of malignant cells or
tumor vasculature) with effector sequences (that cause the
lysis of the targeted cell type)1–3, or alternatively by local
administration of the oncolytic peptide into the neoplastic
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lesion, notably by direct injection4–8. Lytic peptides
usually combine two physicochemical features, namely
lipophilicity and cationic charge, meaning that they con-
tain hydrophobic and positively charged amino acids
(mostly arginine and lysine residues) that may be inter-
spersed in a way to create an amphipathic structure9. It is
thought that this design facilitates the enrichment of the
peptides within the cell and, in particular, the mito-
chondrial matrix as a result of their electrophoretic dis-
tribution following the Nernst equation10, hence allowing
them to mediate local membrane-permeabilizing effects
that compromise organellar and cellular integrity11.
Although the overall molecular design of oncolytic
peptides follows the rules exposed above, there may be
major, hitherto unexplained differences in the subcellular
distribution of such agents. For example, the oncolytic
peptide LTX-315 follows a classical pattern of mito-
chondrial distribution causing early permeabilization of
this organelle with the dissipation of the mitochondrial
transmembrane potential and the release of inter-
membrane proteins including cytochrome c and DIABLO
through the outer membrane11,12. In sharp contrast,
oncolytic, LTX-401, an amphipathic β(2,2)-amino acid
derivative, tends to enrich in the Golgi apparatus and
dismantles the organelle before mitochondrial integrity is
compromised4,8,13. This mitochondrial step of the cell
death cascade appeared to be important for cell death
induction by both LTX-315 and LTX-401, because
knockout of the proapoptotic multidomain BCL2 family
proteins BAX and BAK attenuated cell killing by both
LTX-315 and LTX-4018,11. These differences and simila-
rities illustrate the complexity of pro-death signaling
mediated by agents that apparently share comparable
physicochemical properties.
Over the past few years, it has become increasingly
clear that anticancer drugs should not only be optimized
with respect to their capacity to kill a significant (and
ideally close-to-total) fraction of malignant cells and
hence to “debulk” the primary tumor and its metastases.
Rather, antineoplastics should also be able to stimulate
anticancer immune responses, an effect that can be
achieved by a variety of mechanisms, namely, (i) killing
of cancer cells in a way that leads to the release or
exposure of danger-associated molecular patterns
(DAMPs) that will alert the innate and later the acquired
immune system to recognize tumor-associated antigens,
(ii) direct stimulation of immune effectors or subversion
of immunosuppressive mechanisms14–16. Indeed, it is
difficult to conceive that any kind of cancer treatment
would be able to eliminate the very last malignant cell
(among 1010 to 1012 neoplastic cells) and hence to
achieve definitive cure, a scenario that would apply if
anticancer immunosurveillance was not involved in
long-term treatment outcomes.
One mechanism that appears to be particularly impor-
tant for triggering antineoplastic immune responses is the
induction of immunogenic cell death (ICD), tied to the
cell surface exposure of the DAMP calreticulin, an “eat-
me” signal for dendritic cell (DC) precursors, as well as
the release of several DAMPs including ATP and HMGB1
that attract DCs into the proximity of cancer cells and
activate them for optimal tumor antigen cross-
presentation to cytotoxic T lymphocytes17–21. Of note,
both LTX-315 and LTX-401 are able to stimulate ICD,
meaning that cancer cells killed by these agents in vitro
can elicit protective antitumor immune responses upon
their inoculation in vivo and that local administration of
either LTX-315 or LTX-401 triggers signs of an immune
response in established tumors4–8,13,22,23. For this indi-
cation, LTX-315 is currently undergoing clinical trials
(NCT01986426; clinicaltrials.gov).
Based on the aforementioned premises, the develop-
ment of oncolytic peptides is currently expanding.
Recently, a new class of oncolytic peptides (DTT peptides)
with antilymphoma activity were reported24. Several
new analogues were designed and tested against hepato-
cellular and colorectal carcinoma cell lines (Table 1). In
this report, we analyzed the cellular and immunological
mode of action of two novel oncolytic DTT-analogues,
DTT-205 and DTT-304. Here, we report that both
agents selectively target lysosomes and share some but
not all of their cytotoxic mechanisms of action. Impor-
tantly, both DTT-205 and DTT-304 can cause the total
eradication of established mouse cancers as they induce
a potent, therapeutically relevant antitumor immune
response.
Results and discussion
Morphological effects of DTT-205 and DTT-304
When added to human cancer cells, DTT-205 or DTT-
304 stimulated a necrosis-like disruption of cellular
morphology. In cells in which the plasma membrane was
still intact and hence retaining the cytoplasm, lipid dro-
plets in the cytoplasm were a prominent morphological
feature (Fig. 1a) that was induced in a dose-dependent
fashion (Fig. 1b, c), as determined by transmission elec-
tron microscopy. Staining with the red fluorescent lipo-
philic dye Nile red confirmed the formation of lipid
droplets in the cytoplasm of cells treated with DTT-205 or
DTT-304 that occurred in a time and dose-dependent
fashion (Fig. 1d–f). Of note, these effects were only
obtained when cellular metabolism and membrane traf-
ficking were active at 37 °C, yet not at lower temperatures
such as 14 or 22 °C (Fig. 1g, h). As for other oncolytic
peptides such as LTX-31525 and LTX-4018, DTT-205 and
DTT-304 lost their cytotoxic potential in the presence of
serum (Supplementary Figure S1). However, DTT-205
and DTT-304 differed from LTX-315 and LTX-401 in the
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sense that only the DTT peptides, but not the LTX
compounds, induced lipid droplets (Supplementary
Figure S2).
Lysosomal tropism of DTT-205 and DTT-304
Intrigued by the peculiar morphology of DTT-treated
cells, we investigated the subcellular distribution of
these agents, taking advantage of DTT-205 and DTT-
304 that had been modified to attach a blue-fluorescent
moiety to the molecules. Cells that express fluorescent
biosensors in the nucleus (histone H2B fused to red
fluorescent protein, RFP), endoplasmic reticulum (cal-
reticulin, CALR fused to green fluorescent protein,
GFP), Golgi apparatus (GALT1 fused to GFP), mito-
chondria (DIABLO fused to GFP), or lysosomes
(LAMP1 fused to GFP) were incubated with the fluor-
escent derivatives of DTT-205 and DTT-304. Confocal
fluorescence microscopy revealed that both DTT-205
and DTT-304 co-localized with the lysosomal
marker LAMP1-GFP but not with any other organellar
probe (Fig. 2a–d). Of note, this colocalization was
abrogated upon preincubation of the cells with the
vacuolar ATPase inhibitor bafilomycin A1 (BAFA1),
which is known to abolish lysosomal acidification
(Fig. 2b–d). As other lysosomotropic agents26, DTT-205
and (less so) DTT-304-affected lysosomal stability and
let to a reduction in measurable organellar surface
area as detected by LysoTrackerTM (Fig. 2e–g). Next,
we determined whether the lysosomotropism of DTT-
205 and DTT-304 might explain their cytotoxic activity.
For this, we used BAFA1 to avoid their lysosomal
accumulation (Fig. 2b), finding that this maneuver par-
tially reduced cell killing by DTT-205 or DTT-304
(Fig. 2h, i).
Apoptosis-related signaling induced by DTT-205 and
DTT-304
Caspase-3 activation is one of the biochemical hall-
marks of apoptosis27. While a significant fraction of cells
treated with the positive control, the pan-tyrosine kinase
inhibitor staurosporine stained positively with an anti-
body recognizing the proteolytically mature fragment of
caspase-3, only a minor fraction of cells exhibited cas-
pase activation after treatment with DTT-205 or DTT-
304 (Fig. 3a–d). Both DTT-205 and DTT-304 caused
nuclear shrinkage, though without the formation of
apoptotic bodies, and a decrease in the number of
analyzable cells (Fig. 3a–c, e, f; Supplementary Fig. 3).
The pan-caspase inhibitor z-VAD-fmk failed to prevent
cell killing by DTT-205 or DTT-304 (Fig. 3g, h), as did
the ferroptosis inhibitor ferrostatin-1. In contrast, two
antioxidants, namely N-acetylcysteine and glutathione
strongly reduced the cytotoxic activity of DTT-205 and
DTT-304 (Fig. 3g–j, Supplementary Figure 4). Apopto-
tic signaling also involves the mitochondrial membrane
permeabilization that often depends on the expression
of proapoptotic multidomain members of the BCL2
family such as BAX and BAK. Indeed knockout of BAX,
alone or together with BAK, reduced killing by DTT-205
or DTT-304 to a variable extent (Fig. 3k, l). In synthesis,
Table 1 Peptide design and IC50 values of DTT peptides against various cell lines
Compound JM1 BEL-7402 HEPG2 HepaRG CT-26 HT-29 CC531 MRC-5 HUVEC hRBCs
DTT-106 17.5 ± 4.2 27.1 ± 0.5 27.05 ± 0.6 24.1 9.7 ± 0.4 25.8 ± 1.2 26.7 ± 4.3 28.6 ± 2.4 29.3 ± 0.2 ND
DTT-201 26 ± 3.0 > 31 > 31 ND 10.8 ± 1.3 > 31 > 31 > 31 > 31 ND
DTT-202 15.9 ± 2.3 > 31 > 31 23.3 ± 0.9 7.4 ± 1.6 23.4 ± 0.5 16.5 ± 1.4 23.3 ± 2.2 29.9 ± 1.2 ND
DTT-203 13.4 ± 5.9 19.0 ± 1.3 23.4 ± 3.1 22.6 8.1 ± 0.6 26.5 ± 0.9 > 31 30.5 ± 1.7 29.5 ± 0.8 ND
DTT-204 16.4 ± 1.0 22.9 ± 0.8 > 31 ND 8.1 ± 1.2 16.5 ± 3.4 25.2 ± 0.4 24.0 ± 3.0 27.5 ± 2.5 ND
DTT-205 6.9 ± 1.7 10.3 ± 0.3 23.6 ± 0.7 9.0 ± 0.3 8.2 ± 0.5 9.8 ± 0.9 13.0 ± 0.3 11.2 ± 0.1 10.6 ± 2.6 526–614
DTT-122 > 31 > 31 > 31 ND ND > 31 ND ND ND ND
DTT-301 26.0 ± 2.9 > 31 > 31 ND 6.7 ± 0.6 > 31 > 31 > 31 > 31 ND
DTT-302 16.3 ± 1.2 > 31 24.5 ± 3.4 21.1 10.1 ± 1.5 > 31 > 31 > 31 > 31 ND
DTT-303 13.0 ± 0.8 19.5 ±2.4 20.2 ± 3.6 28.5 6.0 ± 0.5 > 31 25.8 ± 5.8 26.7 ± 3.4 > 31 ND
DTT-304 13.0 ± 1.3 16.4 ± 0.2 21.4 ± 0.3 15.0 ± 2.1 8.6 ± 2.6 21.1 ± 1.7 24.3 ± 6.7 29.0 ± 2.0 27.9 ± 2.1 > 928
DTT-305 12.4 ± 2.0 15.8 ± 0.05 20.6 ± 2.4 14.8 ± 0.4 7.8 ± 2.0 9.0 ± 0.8 15.7 ± 0.3 12.4 ± 0.2 15.0 ± 0.3 ND
DTT-306 8.7 ± 0.7 11.6 ± 0.5 20.1 ± 2.8 12.5 7.5 ± 1.7 4.7 ± 0.9 13.1 ± 2.1 17.5 ± 2.3 16.4 ± 1.5 ND
hRBCs human red blood cells, ND not determined
Data represents two or more independent experiments conducted in triplicates (IC50 μM ± SD). Standard concentration gradient 1–100 μg/ml, equaling ∼0.3–31 μM
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it appears that pro-oxidant and BAX/BAK-dependent
processes, but not caspase activation, participate to cell
killing by DTT-205 or DTT-304.
Necroptotic signaling induced by DTT-205 and DTT-304
To investigate the potential role of necroptotic signaling
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Fig. 1 DTT peptides induce the formation of lipid droplets. Human osteosarcoma U2OS cells were treated with 2.5 µM of either DTT-205 or DTT-
304 for 6 h. Cells were fixed and subjected to electron microscopy. The overview micrographs in the upper panel depict necrotic morphologies (N) of
some of the treated cells and the high magnification micrographs in the lower panel show the formation of lipid droplets (L) in intact cells. Size bars
equals 10 µm (upper panel) and 1 µm (lower panel). Representative images (a) and quantifications (b, c) are depicted (mean ± SD of a minimum of
five view fields). The formation of lipid droplets in response to increasing doses from 0.65 to 10 µM DTT peptides was quantified by means of the
lipophilic dye Nile Red at 6 h and 24 h post treatment in epifluorescence microscopy. Representative images (d) and quantifications (e, f) are shown
(mean ± SD of triplicate assessments, Student’s t test, p < 0.5, **p < 0.01). Temperature dependency of the lipid droplet formation was assessed by
keeping the cell cultures upon treatment with 0.65 to 10 µM DTT-205 (g) and DTT-304 (h) at the indicated temperature for 6 h before Nile Red
staining. Increased number of lipid droplets at physiological temperature is indicative for an underlying active biochemical reaction (mean ± SD of
triplicate assessments, Student’s t test, *p < 0.5, **p < 0.01)
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Fig. 2 Organellar targeting of DTT-205 and DTT-304. Human osteosarcoma U2OS cells stably expressing the nuclear marker histone H2B together
with red fluorescent protein (RFP), the ER marker calreticulin (CALR) labeled with green fluorescent protein (GFP), galactose-1-phosphate
uridylyltransferase GALT1, a marker of the Golgi apparatus fused to GFP, DIABLO co-expressing GFP as an indicator for mitochondria and LAMP1-GFP
as a lysosomal marker were treated with 1.25 µM Pacific blue-labeled DTT peptides in the presence or absence of lysosomal acidification that was
blocked or not with bafilomycin A1 (BAFA1). Both DTT-205 and DTT-304 accumulated in lysosomal structures, an effect that was inhibited with
BAFA1. Representative images of confocal assessment (a, b; size bar equals 5 µm) and relative cooccurrence of Pacific Blue label with organellar
markers was assessed (c, d; mean ± SEM of a minimum of five view fields). Wild-type U2OS cells were stained with LysoTracker green and the
decrease in lysosomal content was assessed upon treatment 0.65 or 1.25 µM DTT peptides for 6 h by epifluorescence microscopy. Representative
images (e) and quantifications (f, g) are depicted (size bar equals 10 µm; mean ± SD of triplicate assessments, Student’s t test, *p < 0.5). Viability was
measured in living cells by means of the exclusion dye propidium iodide 6 h post treatment with 0.65 to 10 µM DTT-205 (h) and DTT-304 (i) in the
presence or absence of BAFA1 by live cell microscopy (mean ± SD of triplicate assessments, Student’s t test, *p < 0.5, **p < 0.01, ***p < 0.001). BAFA1
partially decreased the cytotoxic effect of the DTT peptides
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Fig. 3 (See legend on next page.)
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advantage of a biosensor cell line that lacks MLKL (and
hence cannot undergo necroptosis) yet expresses a RIP3-
GFP fusion protein that can be monitored for its aggre-
gation in the cytoplasm within so-called “necropto-
somes”28,29. As a positive control, a combination of tumor
necrosis factor-α (TNFα), DIABLO mimetic, and z-VAD-
fmk (collectively abbreviated as ‘TSZ’) induced full
necroptosome activation. DTT-205 was unable to induce
this phenomenon, while DTT-304 turned out to cause
necroptosome activation in a time-dependent and
concentration-dependent fashion (Fig. 4a–d). Accord-
ingly, cells treated with DTT-304 (but not DTT-205)
manifested the phosphorylation of the RIP3 substrate
MLKL (Fig. 4e, f). Cells rendered deficient for RIP3 or
MLKL30 became partially resistant against cell killing by
DTT-304 (but not DTT-205) (Fig. 4g, h), supporting the
notion that DTT-304 (but not DTT-205) can activate a
cell death signaling pathway that involves the necroptotic
cascade.
Immunogenic cell death triggered by DTT-205 and
DTT-304
ICD is characterized by the cellular release/exposure of
DAMPs (such as CALR, HMGB1 and type-1 interferons)
that make dead-cell antigens recognizable to the immune
system. Both DTT-205 and DTT-304 triggered CALR
exposure on the cell surface (Fig. 5a, b), nuclear HMGB1
exodus (Fig. 5c, d), and the transcription of genes coding
for type-1 interferons (Fig. 5e, f). Nevertheless, the treat-
ment with oncolytic peptides did not lead to an increase
in the expression of major histocompatibility complex
class I molecules (MHC-I) (Supplementary Figure 5) and
depicted a rather unspecific cytotoxicity on both cancer
and immune cells (Supplementary Figure 6). Based on
these in vitro characteristics of DTT compound-induced
cell death, we next investigated whether these agents
might mediate anticancer effects through the stimulation
of an anticancer immune response. For this, established
MCA205 fibrosarcomas growing on immunocompetent
haploidentical C57BL/6 mice were injected with either
DTT-205 or DTT-304, which both caused complete
oncolysis in most surviving mice. Of note, prior depletion
of T cells by injection of specific antibodies blocking CD4
and CD8 abolished these anticancer effects. These
immune-dependent anticancer effects of DTT-205 and
DTT-304 were evident both when tumor growth kinetics
and overall survival of mice were monitored (Fig. 6a–g).
Rechallenge of mice that had been cured from MCA205
cancers with the same tumor type (MCA205) was
incompatible with the development of cancers, although
antigenically distinct TC-1 lung adenocarcinoma grew in
most (eight out of nine) cases (Fig. 6h–k). Very similar
results were obtained when TC-1 carcinomas instead of
MCA205 sarcomas were treated with DTT-205 or DTT-
304. All animals that could be monitored were cured from
their cancers (Supplementary Figure 7A–E), and none of
the cured animals that were rechallenged with TC-1
developed cancers, although MCA205 tumors readily
developed (Supplementary Figure 7F–H). Animals bear-
ing TC-1 tumors on both flanks that were treated with the
oncolytic peptides only on one side, but not on the other
depicted abscopal effects that led to the reduction of
tumor growth in the distant lesion (Supplementary Fig-
ure S8). These results indicate that immune-dependent
cancer cure mediated by DTT-205 or DTT-304 is coupled
to the establishment of systemic immunity that mediates
long-term immune memory specific for the eradicated
cancer type.
Concluding remarks
The results of this study suggest that the oncolytic
peptides DTT-205 and DTT-304 both target lysosomes as
indicated by their selective accumulation in this organelle.
To this respect, DTT-205 and DTT-304 are rather dis-
tinct from other oncolytic peptides that often target the
mitochondria. Despite their common lysosomotropic
nature, DTT-205 and DTT-304 are to a certain extent
different in their mode of action. While cell death induced
by both agents strongly depends on the production of
reactive oxygen species exclusively DTT-304 shows pro-
necroptotic features, such as the formation of the
necroptosome and the phosphorylation of MLKL.
(see figure on previous page)
Fig. 3 Cell death induced by DTT-205 and DTT-304. Human osteosarcoma U2OS cells were treated with 0.65 to 10 µM DTT peptides for the
indicated time and following assessed for the activation of caspase-3 (CASP3). The pan-kinase inhibitor staurosporine (STS) was used as positive
control. Representative images (a, b) and quantifications of CASP3 activation (c, d) are depicted while pyknosis was assessed by measuring the
decrease in Hoechst 33342-stained nuclear area (e, f) by conventional microscopy (size bar equals 10 µm; mean ± SD of triplicate assessments,
Student’s t test, *p < 0.5, **p < 0.01, ***p < 0.001). In order to assess the cell death modality, U2OS cells were pretreated with the ferroptosis inhibitor
ferrostatin-1 (FER-1), the pan-caspase inhibitor zVAD-fmk (zVAD) or the antioxidants N-actylcystein (NAC) and reduced glutathione (GSH) before the
addition of 2.5 µM of DTT peptides (g, h). Exclusively the inhibition of reactive oxygen species (ROS) generation decrease the cytotoxic effects of both
DTT-205 and DTT-304 in a dose-dependent fashion (i, j, mean ± SD of triplicate assessments, Student’s t test, *p < 0.5, **p < 0.01, ***p < 0.001). Mouse
embryonic fibroblasts (MEFs) that were either wild type, single- or double knockout for the proapoptotic proteins Bax and/or Bak were treated with
0.65 to 10 µM of DTT-205 or DTT-304 and viability was assessed by means of an exclusion dye in epifluorescence microscopy (k, l; mean ± SD of
triplicate assessments. Student’s t test, *p < 0.5, **p < 0.01, ***p < 0.001). Single as well as double knockouts were partially resistant to DTT-peptide-
induced cell death
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Nevertheless, analogue to similar oncolytic peptides
such as LTX-315 and LTX-4014-8,12,23 both DTT-205 and
DTT-304 triggered the emission of pro-immunogenic
DAMPs in vitro and activated anticancer immune
responses in vivo. Complete tumor lysis by DTT peptides
required repeated intratumoral injections, which might
become a challenging aspect during clinical translation
but might facilitate to render the tumor into its own
vaccine31. Thus, in this study animals that were cured
from primary tumors generated long-term immunological
memory that mediated the rejection of isogenic tumors,
which underlines the immunotherapeutic potential of
oncolytic peptides in general and DTT-205 and DTT-304
in particular.
Materials and methods
Chemicals and cell cultures
Cell culture media and supplements were purchased
from Thermo Fisher Scientific (Carlsbad, CA, USA) and
chemicals came from Sigma-Aldrich (St. Louis, MO, USA)
with the exception of LTX-315, LTX-401, DTT-205, and
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Fig. 4 Necroptotic traits induced by DTT-304 but not by DTT-205. Human colon carcinoma HT-29 cells knockout for MLKL and stably expressing
RIP3 coupled to green fluorescent protein (GFP) were treated with 0.65 to 10 µM DTT peptides for the indicated time and following assessed for the
aggregation of RIP3 indicative for necroptosome formation by epifluorescence microscopy. The combination of TNFα (T), SMAC/DIABLO mimetic
peptide B6 (S), and the pan-caspase inhibitor z-VAD-fmk (Z) was used as positive control for the induction of necroptosis. Representative images
(a, c) and quantifications of RIP3 aggregates (b, d) are depicted (size bar equals 10 µm; mean ± SD of triplicate assessments, Student’s t test, *p < 0.5,
**p < 0.01, ***p < 0.001). Downstream MLKL activation was visualized with phosphoneoepitope-specific antibody (e, f) Of note, exclusively DTT-304
but not DTT-205 depicted traits of necroptosis. Murine lung cancer TC-1 cells that were CRISPR gene edited in RIP3 and MLKL were treated with 0.65
to 10 µM of DTT-205 or DTT-304 for 6 h and viability was assessed by means of an exclusion dye (g, h; mean ± SD of triplicate assessments, Student’s
t test, *p < 0.5, **p < 0.01, ***p < 0.001). Knockouts of RIP3 and MLKL were partially resistant to DTT-304 yet not to DTT-205-induced cell death
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Norway). Plasticware was obtained from Greiner Bio-One
(Monroe, CA, USA), primary antibody (cleaved caspase-3;
#9661) came from Cell Signaling (Danvers; MA; USA), and
AlexaFluor-coupled secondary antibody from Thermo
Fisher Scientific. Anti-CD4 and anti-CD8 antibodies for
in vivo use were obtained from BioXcell (West Lebanon,
NH, USA). Mouse embryonic fibroblast (MEF), mouse
sarcoma cells MCA205, murine lung cancer TC-1,
human osteosarcoma U2OS, wild type or stably
expressing GALT1-GFP, H2B-RFP, CALR-GFP, DIABLO-
GFP or LAMP1-GFP, and HT-29 stably expressing RIP3-
GFP28 cells were cultured in Glutamax®-containing DMEM
medium supplemented with 10% fetal calf serum (FCS),
and 10mM HEPES. Cells were grown in a humidified
incubator at 37 °C under a 5% CO2 atmosphere.
Murine thymocytes and splenocytes were obtained
by dispersing organ extracts in Glutamax®-containing




























































































































































































Fig. 5 DAMP release from tumor cells treated with DTT-205 and DTT-304. The exposure of calreticulin (CALR) in human osteosarcoma U2OS
cells was measured by flow cytometry using polyclonal anti-CALR antibody while excluding cells that lost cytoplasmic membrane integrity and thus
incorporated the exclusion dye propidium iodide (PI) (a, b). Exodus of high mobility group box 1 (HMGB1) from the cells into cell culture
supernatants was monitored by HMGB1-specific enzyme-linked immunosorbent assay ELISA. Absorbance was measured and concentrations were
calculated based on standards (c, d). Both CALR and HMGB1 were emitted by both DTT-205 and DTT-304 in a dose-dependent fashion. The
production of type I interferon (IFN) was measured in by reverse transcription quantitative real time polymerase chain reaction qRT-qPCR from
purified mRNA of cells treated with DTT compounds (e, f) (mean ± SD of triplicate assessments; Student’s t test, *p < 0.5, **p < 0.01, ***p < 0.001). In
summary some ICD DAMPs were release in response to DTT-205 and DTT-304
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and FCS and HEPES as described above. Erythrolysis was
conducted using ACK lysis buffer (Thermo Fisher
Scientific).
HMGB1 release assays
Cells were seeded in 24-well plate and let adhere and
adapt overnight, before they were treated with the DTT
peptides. Supernatants were collected and centrifuged at
500 × g for 5 min in order to remove cellular debris.
Released HMGB1 protein content was quantified in
supernatants by ELISA (#ST51011; IBL, Hamburg, Ger-
many) according to the manufacturer’s recommendations,
and samples were measured with a Paradigm E3 multi-
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Fig. 6 In vivo activity of DTT-205 and DTT-304 in immunocompetent animals. Mouse fibrosarcoma cells were inoculated subcutaneously in
syngenic C57BL/6 animals and arising tumors were treated when palpable with repeated injections of DTT-205 or DTT-304 in the presence of
absence of intraperitoneally injected CD4/CD8 blocking antibody (a). Both DTT-205 and DTT-304-induced efficient oncolysis. Immunocompetent
animals depicted long-term effects whereas tumors recurred soon after treatment in immunecompromised animals upon T-cell depletion an effect
that is reflected in tumor growth (b-f) and overall survival (g) (Chi2 test, **p < 0.01, ***p < 0.001). Rechallenge of animals cured from MCA205
fibrosarcoma with MCA205 several weeks after the initial therapy on the contralateral and challenge with syngenic mouse TC-1 lung cancer cells on
the ipsilateral side resulted in efficient rejection of MCA205 but aggressive tumor growth of TC-1 (h-k). DTT-205 and DTT-304 caused the generation
of immunological memory that sufficed in rejection isogenic tumors
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Western blot
Half a million cells were harvested from six-well plates
resuspended in lysis buffer containing 150 mM sodium
chloride, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1%
SDS, and protease inhibitor cocktails (Complete protease
inhibitor cocktail, Roche, Basel, Switzerland) and incu-
bated on ice for 30min. To obtain supernatant, cell lysate
was centrifuged at 12000×g for 20min at 4 °C to remove
insoluble materials. The lysate was mixed with 4 ×
NuPAGE® LDS sample buffer and 10 × sample reducing
agent, and proteins were denaturated at 100℃ for 10 min.
NuPAGE® Novex® 4–12% Bis-Tris Protein Gels (Thermo
Fisher Scientific) were used for protein electrophoresis
under a 100 V constant voltage mode. Separated proteins
were transferred from gel to PVDF membrane (Merck-
Millipore, Darmstadt, Germany). After blocking with 5%
BSA in 1 × TBS containing 0.1% Tween®−20 (1 × TBST)
for 1 h at room temperature, the membranes were probed
with corresponding primary antibodies at 4 °C overnight:
anti-mouse MLKL polyclonal antibody (AP14272b;
Abgent, San Diego, CA, USA). To visualize phosphory-
lated MLKL (pMLKL), anti-mouse MLKL (phospho S345)
monoclonal antibody (ab196436, Abcam) was used. The
membranes were then washed and incubated with HRP-
conjugated secondary antibodies (SouthernBiotech, Bir-
mingham, AL, USA) at room temperature for 1 h. The
peroxidase activity was detected with ECL Western
Blotting Detection Reagent (GE healthcare, Chicago, IL,
USA) and images were acquired by ImageQuant LAS
4000 (GE healthcare).
RNA extraction, reverse transcription, and qRT-PCR
Cells were collected for total RNA extraction using the
RNeasy Mini kit (Quiagen, Hilden, Germany). Three
micrograms of RNA were reverse-transcribed to cDNA
using SuperScript® III First-Strand System (Thermo
Fisher Scientific). Type I IFN-related gene expression was
quantified with TaqMan® Gene Expression Assays using
Universal Master Mix II (with UNG) on a StepOnePlus™
Real-Time PCR system (all from Thermo Fisher Scien-
tific). GAPDH was used as house-keeping gene for nor-
malization. Relative gene expression was quantified using
the comparative Ct method and was calculated as fold
change. All experiments were conducted in triplicate
assessment.
High-throughput assessment of cell death
In total, 5 x 103 U2OS cells were seeded into black 96-
well µclear imaging plates (Greiner Bio-One) and allowed
to adapt for 24 h. Thereafter the cells were treated with
the DTT compounds and respective controls and incu-
bated for additional 6 or 24 h before either 1 µM of DAPI
or a mixture of 1 µM Hoechst, and 1 µM propidium
iodide were added immediately before monitoring the
uptake of the exclusion dye in a minimum of four view
fields per well by means of an ImageXpress micro XL
automated bioimager (Molecular Devices) equipped with
a PlanApo 20 × /0.75 NA objective (Nikon, Tokyo, Japan).
Immunostaining
In total, 5 x 103 U2OS cells were seeded into black 96-
well µclear imaging plates (Greiner Bio-One) and allowed
to adapt for 24 h. Thereafter, the cells were treated with
DTT compounds and respective controls and incubated
for additional 6 or 24 h before fixation in 3.7% (w/v)
paraformaldehyde (PFA) in PBS supplemented with 1 µM
Hoechst 33342 for 20min. Upon fixation, cells were
permeabilized with 0.1% Triton in PBS for 10min at RT.
Unspecific binding was blocked with 2% BSA in PBS for
10min at RT followed by primary antibody diluted in BSA
2% following the manufactures recommendations over-
night on an orbital shaker at 4 °C. The cells were rinsed
twice and stained with AlexaFluor-coupled secondary
antibodies for 1 h at RT, rinsed twice and subjected to
imaging using an ImageXpress micro XL automated
bioimager (Molecular Devices) equipped with a PlanApo
20 × /0.75 NA objective (Nikon).
High-content screening microscopy
U2OS cells stably expressing GALT1-GFP, CALR-
KDEL-GFP, H2B-RFP, LAMP1-GFP, and DIABLO-GFP
or HT-29 cells stably expressing RIP3-GFP were seeded in
96-well black microplates for 24 h. After treatment, cells
were fixed with 3.7% PFA for 20min at room temperature
and stained with 10 µg/ml Hoechst 33342 in PBS. Image
acquisition was performed using an ImageXpress Micro
XL automated microscope (Molecular Devices). A mini-
mum of four view fields were captured per well. Upon
acquisition, images were analyzed using the Custom
Module Editor of the MetaXpress software (Molecular
Devices). Briefly, cells were segmented and divided into
nuclear and cytoplasmic regions based on the nuclear
Hoechst staining and GFP or RFP cytoplasmic signals.
GFP-LC3 and RIP3-GFP dots were detected using auto-
mated thresholding, and their number and surface were
measured in the cytoplasmic compartment. Cooccurrence
of GALT1-GFP, CALR-KDEL-GFP, H2B-RFP, LAMP1-
GFP, and DIABLO-GFP fluorescence signals with Pacific
Blue-labeled DTT compounds were systematically ana-
lyzed to assess subcellular targeting. Data processing and
statistical analyses were performed using the R software
(http://www.r-project.org/).
Transmission electron microscopy
For ultrastructural studies, human osteosarcoma U2OS
cells were fixed in 1.6% glutaraldehyde (v/v in 0.1M
phosphate buffer) for 1 h, collected by scraping, cen-
trifuged, and the pellet was postfixed 1% osmium
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tetroxide (w/v in 0.1M phosphate buffer). Following
dehydration through a graded ethanol series, cells were
embedded in Epon™ 812 and ultrathin sections were
stained with standard uranyl acetate and lead citrate.
Images were taken using a Tecnai 12 electron microscope
(FEI, Eindhoven, the Netherlands).
Data processing and statistical analyses
Unless otherwise specified, experiments were performed
in triplicate parallel instances and repeated at least once,
and data were analyzed with the R software (http://www.
r-project.org/). Microscopy images were segmented and
analyzed by means of the MetaXpress (Molecular Devi-
ces) software and numerical data was further processed
with R. Unless otherwise specified, data are presented as
means ± SD. Thresholds for the minimum number of
events in each analysis necessary to apply further statistics
were calculated based on a medium effect size (according
to Cohen’s conventional criteria) using the pwr package
for R with a targeted value of 0.95. Samples that did not
match the requirements were marked ND and were
excluded from the analysis.
Determination of surface-exposed CALR or MHC-I by
immunofluorescence
Cells were collected and rinsed twice with cold PBS.
Following the cells were incubated with an anti-CALR
antibody (ab2907; Abcam, Cambridge, UK) or anti-MHC-
I antibody (12-5958-82, eBioscience, San Diego, CA, USA)
diluted in cold blocking buffer (1% BSA in PBS) for
60min on ice, followed by washing and incubation with
AlexaFluor 488-conjugates (Invitrogen) in blocking buffer
(for 30 min). Thereafter cells were washed in cold PBS, the
vital dye propidium iodide (PI) or Zombie UV was added
to a final concentration of 1 μg/mL, and samples were
analyzed by means of a CyAn ADP (Beckman Coulter,
Brea, CA, USA) coupled to a HyperCyt autosampler
(IntelliCyt; Albuquerque, NM, USA). The analysis was
limited to living (PI−) cells. Data were statistically eval-
uated using R (https://www.r-project.org).
Mouse experiments
Female wild-type C57BL/6 mice at the age of 6–8 weeks
were obtained from Harlan France (Gannat, France) and
maintained in the animal facility at Gustave Roussy
Campus Cancer in specific pathogen–free conditions in a
temperature-controlled environment with 12 h light, 12 h
dark cycles, and received food and water ad libitum.
Animal experiments were in compliance with the EU
Directive 63/2010 and protocols 2013_094A and were
approved by the Ethical Committee of the Gustave Roussy
Campus Cancer (CEEA IRCIV/IGR no. 26, registered at
the French Ministry of Research). MCA205 tumors were
established in C57BL/6 hosts by subcutaneously
inoculating 500.000 cells. When tumors became palpable,
1.5 mg of DTT peptides were injected intratumorally.
Four days later, remaining tumor tissue was treated
accordingly and mice well-being and tumor growth were
monitored. Anti-CD8 and anti-CD4 i.p. injections were
repeated every 7 days to assure the complete depletion of
both T cell populations during the whole experiment.
Animals were sacrificed when tumor size reached end-
point or signs of obvious discomfort associated to the
treatment were observed following the EU Directive 63/
2010 and our Ethical Committee advice. Surviving and
tumor-free animals were analyzed and kept for more than
30 days before rechallenge with 5 × 105 live TC-1 and
MCA205 cells injected contralateral in case of MCA205
previously-injected tumor-free animals. In case of
previously-injected TC-1 tumor-free animals the location
of the injected cells was inverted. Animals were mon-
itored and tumor growth documented regularly until end-
points were reached or signs of obvious discomfort were
observed. Statistical analysis was performed employing
two-way ANOVA analysis followed by Bonferroni’s test
comparing to Ctr conditions (*p < 0.05, **p < 0.01, and
***p < 0.001).
Peptide synthesis
All peptides were synthesized on solid-phase with a
Prelude instrument (Protein Technologies Inc. Tucson,
AZ, USA) using standard Fmoc protocols and amino acid
derivatives. All synthesized peptides were prepared as C-
terminal amides by using a Rink amide resin (Nova-
biochem, Merck-Millipore, Billerica, MA, USA) as solid
support. The Fmoc-amino acids used were standard
derivatives from Novabiochem. Double couplings (2 ×
30min, 5 eq to the resin) were performed. The incoming
Fmoc-amino acids were activated with 5 eq (2-(6-chloro-
1H-benzotriazole-1-yl)−1,1,3,3-tetramethylaminium hex-
afluorophosphate) (HCTU) and 10 eq diisopropylethyla-
mine (DIPEA) with dimethylformamide (DMF) as solvent.
Coupling reactions were concluded with a washing (DMF,
3 × 30 s) and Fmoc-removal step (20% piperidine in DMF,
5+ 10min). For microscopy studies, the peptides were
fluorescently labeled at their C-termini with Pacific Blue™
(Exmax= 410 nm, Emmax= 455 nm). This was achieved by
using a Universal NovaTag resin (Novabiochem, Merck-
Millipore, Billerica, MA, USA) as solid support. Before
removing the final Fmoc-group, the resin was treated with
2% trifluoroacetic acid (TFA) in dichloromethane (3 ×
1min) and washed with DMF (3 × 30 s) and 1M DIPEA in
DMF (1 × 30 s). The resin was then treated with Pacific
Blue succinimidyl ester (Thermo Fisher Scientific, Wal-
tham, MA, USA) for 1 h. The resin was washed with DMF
(3 × 30 s) and the final Fmoc-group removed. Completed
peptides were cleaved from the resin using a cocktail
containing 95% TFA, 2.5% water, and 2.5%
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triisopropylsilane for 3 h. TFA was removed using a
rotavapor (Hei-VAP Advantage rotavapor, Heidolph
Instruments, Schwabach, Germany) and the fully depro-
tected peptides precipitated with diethyl ether as C-
terminal amides. The ether was decanted and the pre-
cipitated crude peptide allowed to air dry before analysis
and purification.
Peptide purification and characterization
The solvents used in the analytical and preparative
systems were MilliQ water (Solvent A) and acetonitrile
(Solvent B), both modified with 0.1% TFA. The crude and
purified peptides were analyzed on an ACQUITY UPLC
H-class system with a photodiode array (PDA) detector
(Waters, Milford, MA, USA) equipped with an ACQUITY
CEH C18 UPLC column (Waters, 2.1 × 50 mm, 1.7 µm). A
gradient of 0–50% Solvent B over 30min with a flow rate
of 1 mL/min was used, and detection was set at 200–500
nm. The crude peptides were purified to >95% on a
XSelect CSH C18 OBD prep column (19 × 250 mm, 5 µm;
Waters, Milford, MA, USA) installed in an AutoPur-
ificayion System (Waters). A default gradient of 10–40%
Solvent B over 30 min with a flow rate of 20 mL/min was
used, but it was adjusted as required. The detection was
set at 200–500 nm. The molecular weight of the peptides
was confirmed on the Xevo G2 Q-TOF with ACQUITY
UPLC I-Class system (Waters). The purified peptides
were then freeze-dried (Labconco FreeZone 4.5 Plus,
Kansas City, MO, USA) as TFA-salts and stored at −20 °C
until further use.
In vitro cytotoxicity
The MTT assay was adopted to determine cell viability
in a panel of cancerous and non-transformed cells after
4 h incubation with DTT peptides. Pre-cultured cells were
seeded in 96-well plates at a density of 1 × 104–1.5 × 104
cells/well and applied for experiment as previously
described. In short, cells were washed once with serum-
free RPMI 1640 and incubated with increasing con-
centrations of DTT peptides before adding 10 μl MTT
solution to each well. Lastly, acidified isopropanol was
added to facilitate formazan crystal solubilization.
Absorbance was measured at 570 nm on a spectro-
photometric microtiter plate reader (Thermomax Mole-
cular Devices, NJ, USA). Cell survival was calculated as
the A570 nm of DTT-treated cells relative to the negative
control (100% viable cells) using the mean of two or three
independent experiments and expressed as a 50% inhibi-
tory concentration (IC50).
Hemolytic activity
The cytotoxic activity of two selected DTT compounds
(DTT-205 and DTT-304) against human red blood cells
(hRBCs) was determined by a hemolytic assay using freshly
isolated blood from healthy individuals who gave
their signed informed consent. RBCs were resuspended to a
10% hematocrit solution before being incubated for 1 h at
37 °C with DTT compounds dissolved in PBS at con-
centrations ranging from 438–928 μM (1500–3000 μg/ml).
RBCs with PBS and 1% Triton solution alone served as a
negative and positive control, respectively. After centrifu-
ging the samples at 4000 rpm for 5min, the absorbance of
the supernatant was measured at 405 nm on a spectro-
photometric microliter plate reader (Thermomax, Mole-
cular Devices). The protocol used for blood sampling and
handling has been reviewed and approved by the Norwe-
gian Regional Ethic Committee (REK)-approved protocol
(2016/376).
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